^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    CANCER:

    Skin Cancer

    Related cancers:
    1d
    EBNK-ST-001: EBNK-001 Allogeneic NK Cells With Low-Dose IL-15 ± Pembrolizumab in Advanced Solid Tumors (clinicaltrials.gov)
    P1/2, N=83, Recruiting, Essen Biotech
    New P1/2 trial
    |
    Keytruda (pembrolizumab) • cyclophosphamide • fludarabine IV
    1d
    SELECT-CAR-NK: Biomarker-Guided Allogeneic Single-Target or Dual-Target CAR-NK Cell Therapy for Advanced Solid Tumors (clinicaltrials.gov)
    P1/2, N=85, Recruiting, Essen Biotech
    New P1/2 trial • Liquid biopsy
    |
    cyclophosphamide • fludarabine IV
    1d
    Study of RP1 Monotherapy and RP1 in Combination With Nivolumab (IGNYTE) (clinicaltrials.gov)
    P2, N=340, Active, not recruiting, Replimune Inc. | Trial primary completion date: Dec 2025 --> Jun 2028
    Trial primary completion date
    |
    BRAF (B-raf proto-oncogene) • MSI (Microsatellite instability)
    |
    MSI-H/dMMR • BRAF mutation
    |
    Opdivo (nivolumab) • Tudriqev (vusolimogene oderparepvec-wtpg)
    1d
    NCI-2018-01152: MoleMapper, Visiomed, and Confocal Microscopy in Screening Participants for Melanoma (clinicaltrials.gov)
    P=N/A, N=100, Active, not recruiting, OHSU Knight Cancer Institute | Recruiting --> Active, not recruiting
    Enrollment closed
    1d
    Treatment With Amivantamab and Hyaluronidase or Cetuximab for Advanced Skin Cancer in People With a Weakened Immune System (clinicaltrials.gov)
    P2, N=86, Recruiting, National Cancer Institute (NCI) | Not yet recruiting --> Recruiting | Initiation date: Mar 2026 --> Oct 2026
    Enrollment open • Trial initiation date
    |
    mTOR (Mechanistic target of rapamycin kinase)
    |
    Erbitux (cetuximab) • Rybrevant (amivantamab-vmjw)
    2d
    ABCB5: A Key Regulator Linking Stem Cell Plasticity, Tumor Microenvironment, and Therapy Resistance in Cutaneous Melanoma. (PubMed, Cancers (Basel))
    Moreover, ABCB5-positive cells contribute to the formation of an immunosuppressive microenvironment by secreting cytokines (IL-6, IL-8, TGF-β) and expressing immune checkpoint ligands, such as PD-L1, thereby favoring tumor progression and a poor prognosis. This review integrates current data on the molecular and microenvironmental mechanisms underlying melanoma progression and therapy resistance, and positions ABCB5 within the broader landscape of melanoma resistance mechanisms, emphasizing both its potential and its current limitations as a biomarker and therapeutic target.
    Review • Journal • PD(L)-1 Biomarker • IO biomarker
    |
    PD-L1 (Programmed death ligand 1) • BCL2 (B-cell CLL/lymphoma 2) • IL6 (Interleukin 6) • CXCL8 (Chemokine (C-X-C motif) ligand 8) • TGFB1 (Transforming Growth Factor Beta 1) • MIR145 (MicroRNA 145)
    2d
    Navigation Intervention for Adolescent and Young Adult Cancer Survivors (clinicaltrials.gov)
    P=N/A, N=25, Not yet recruiting, Kaiser Permanente
    New trial
    3d
    177Lu-anti-PD-L1 sdAb in Metastatic Solid Tumors (clinicaltrials.gov)
    P1, N=30, Recruiting, Radiopharm Theranostics, Ltd | N=23 --> 30 | Trial completion date: Oct 2025 --> Dec 2027 | Trial primary completion date: Jul 2025 --> Dec 2027
    Enrollment change • Trial completion date • Trial primary completion date • First-in-human
    |
    PD-L1 expression • MSI-H/dMMR
    3d
    Engineered biopolymeric hydrogels for in vitro modeling of equine sarcoid tumors in comparative oncology. (PubMed, Int J Biol Macromol)
    Compared with 2D cultures, 3D models better preserved and upregulated key mesenchymal markers (Vimentin and CDH2). Our findings show how these biomimetic 3D platforms better replicate sarcoid TME, offering a promising tool for comparative oncology and PV-related human cancers.
    Preclinical • Journal
    |
    VIM (Vimentin) • CDH2 (Cadherin 2)
    4d
    Basal Cell Carcinoma With Matrical Differentiation Case Report and Review of Management. (PubMed, Cureus)
    Rare reports of metastasis suggest a potentially more aggressive clinical course than typical BCC. Comprehensive excision and long-term surveillance are recommended to optimize outcomes and further characterize this rare variant.
    Journal
    |
    CTNNB1 (Catenin (cadherin-associated protein), beta 1) • TCHH (Trichohyalin)
    4d
    USP36 inhibits ferroptosis of melanoma cells by stabilizing APEX1. (PubMed, Clin Exp Med)
    Using A375 and SK-MEL-28 melanoma cells treated with the ferroptosis inducer erastin, we analyzed USP36 expression and evaluated its functional role through both overexpression and knockdown experiments...Collectively, these findings establish USP36 as an oncogene in melanoma that inhibits ferroptosis through stabilization of APEX1. Therefore, targeting the USP36-APEX1 axis may represent a novel therapeutic approach for melanoma treatment.
    Journal
    |
    APEX1 (Apurinic/Apyrimidinic Endodeoxyribonuclease 1)
    |
    erastin
    5d
    Vigilant-2: Digital Remote Monitoring of Immune Checkpoint Inhibitor Therapy Induced Toxicity Using the Vigilant App (clinicaltrials.gov)
    P=N/A, N=100, Recruiting, Mayo Clinic | N=30 --> 100 | Trial completion date: Mar 2026 --> Mar 2027 | Trial primary completion date: Mar 2026 --> Mar 2027
    Enrollment change • Trial completion date • Trial primary completion date • Checkpoint inhibition
    |
    Opdivo (nivolumab)